Hemoglobin glycation index and cardiovascular outcomes in patients with coronary intermediate lesions: insights from

Fanzhou Zeng1, Chenxi Song1, Chunyue Wang1

  • 1Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Beijing, China.

Insights

High hemoglobin glycation index (HGI) significantly increases cardiovascular risk in patients with intermediate coronary lesions. This readily accessible biomarker can aid in risk stratification for better patient outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biomarkers

Background:

  • Intermediate coronary lesions pose residual cardiovascular risk despite being hemodynamically non-significant.
  • Hemoglobin glycation index (HGI) is a novel marker reflecting glycemic variability.
  • Assessing HGI's role in predicting outcomes for these patients is crucial.

Purpose of the Study:

  • To evaluate the association between HGI and long-term adverse cardiovascular and cerebrovascular events (MACCEs).
  • To determine if HGI can serve as a biomarker for risk stratification in patients with intermediate coronary lesions.

Main Methods:

  • A cohort of 5932 patients with intermediate coronary lesions was stratified into three HGI tertiles.
  • The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs).
  • A median follow-up of 4.91 years was conducted to assess outcomes.

Main Results:

  • A J-shaped association was observed between HGI and 5-year MACCEs after adjustment.
  • Elevated HGI was a significant independent predictor of MACCEs (HR 1.138 per unit increase, P < 0.001).
  • The High-HGI group exhibited a 76% higher risk of MACCEs compared to the Medium-HGI group (P=0.002).

Conclusions:

  • HGI demonstrates a J-shaped association with MACCEs in patients with intermediate coronary lesions.
  • High HGI is a robust independent predictor of adverse cardiovascular events.
  • HGI is a potentially valuable and accessible biomarker for risk stratification in this patient population.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...